---
title: "Unixell Biotech receives IND clearance by FDA for its Allogeneic iPSC-Derived cell therapy, UX-GIP001, for focal Epilepsy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279043374.md"
description: "In Shanghai on March 13, 2026, Unixell Biotech marked a major achievement when UX-GIP001, its iPSC-derived allogeneic cell therapy for focal epilepsy, received clearance for Investigational New Drug (IND) from the U.S. Food and Drug Administration (FDA) on March 12."
datetime: "2026-03-13T12:07:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279043374.md)
  - [en](https://longbridge.com/en/news/279043374.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279043374.md)
---

# Unixell Biotech receives IND clearance by FDA for its Allogeneic iPSC-Derived cell therapy, UX-GIP001, for focal Epilepsy

In Shanghai on March 13, 2026, Unixell Biotech marked a major achievement when UX-GIP001, its iPSC-derived allogeneic cell therapy for focal epilepsy, received clearance for Investigational New Drug (IND) from the U.S. Food and Drug Administration (FDA) on March 12.

### Related Stocks

- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [UBX.US](https://longbridge.com/en/quote/UBX.US.md)
- [JYB.US](https://longbridge.com/en/quote/JYB.US.md)

## Related News & Research

- [06:31 ETNetherton Syndrome Market Set to Expand During the Forecast Period (2026-2036) as Novel Therapies Enter Development Pipeline | DelveInsight](https://longbridge.com/en/news/286895360.md)
- [4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy](https://longbridge.com/en/news/286655317.md)
- [Analyst Lifts RAPT Therapeutics Price Target to $56 and Reiterates Buy on RAP-219 Seizure Data Upside](https://longbridge.com/en/news/286827447.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [CureDuchenne Announces Partnership with Tevard Biosciences to Advance Suppressor tRNA Therapy for the Treatment of Duchenne Muscular Dystrophy](https://longbridge.com/en/news/287098032.md)